

**Anti-p63 Antibody**  
**Rabbit Polyclonal Antibody**  
**Catalog # AH13596****Specification**

---

**Anti-p63 Antibody - Product Information**

Application	IHC-P, IF, FC
Primary Accession	<a href="#">O9H3D4</a>
Other Accession	<a href="#">137569</a>
Reactivity	Human
Host	Rabbit
Clonality	Polyclonal
Isotype	Rabbit / IgG, kappa
Calculated MW	76785

**Anti-p63 Antibody - Additional Information****Gene ID** 8626**Other Names**

Amplified in squamous cell carcinoma (AIS); Chronic ulcerative stomatitis protein (CUSP); EEC3; Keratinocyte transcription factor KET; LMS; NBP; p40; P51/P63; p53 like transcription factor; p53-related protein p63; RHS; SHFM4; TAp63alpha; TP53CP; TP53L; TP63; TP73; TP73L; Transformation-related protein 63; Trp53rp1; Trp6;3; Tumor protein 63; Tumor protein p53-like; tumor protein p73-like

**Application Note**

IHC-P~~N/A  
IF~~1:50~200  
FC~~1:10~50

**Format**

200ug/ml of Ab purified by Protein A Column. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml.

**Storage**

Store at 2 to 8°C. Antibody is stable for 24 months.

**Precautions**

Anti-p63 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.

**Anti-p63 Antibody - Protein Information****Name** TP63**Synonyms** KET, P63, P73H, P73L, TP73L**Function**

Acts as a sequence specific DNA binding transcriptional activator or repressor. The isoforms

contain a varying set of transactivation and auto-regulating transactivation inhibiting domains thus showing an isoform specific activity. Isoform 2 activates RIPK4 transcription. May be required in conjunction with TP73/p73 for initiation of p53/TP53 dependent apoptosis in response to genotoxic insults and the presence of activated oncogenes. Involved in Notch signaling by probably inducing JAG1 and JAG2. Plays a role in the regulation of epithelial morphogenesis. The ratio of DeltaN-type and TA\*-type isoforms may govern the maintenance of epithelial stem cell compartments and regulate the initiation of epithelial stratification from the undifferentiated embryonal ectoderm. Required for limb formation from the apical ectodermal ridge. Activates transcription of the p21 promoter.

#### **Cellular Location**

Nucleus

#### **Tissue Location**


Widely expressed, notably in heart, kidney, placenta, prostate, skeletal muscle, testis and thymus, although the precise isoform varies according to tissue type. Progenitor cell layers of skin, breast, eye and prostate express high levels of DeltaN-type isoforms. Isoform 10 is predominantly expressed in skin squamous cell carcinomas, but not in normal skin tissues

#### **Anti-p63 Antibody - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

#### **Anti-p63 Antibody - Images**



Formalin-fixed, paraffin-embedded human Prostate Cancer stained with p63 Rabbit Polyclonal Antibody.

#### **Anti-p63 Antibody - Background**

p63 is a homolog of the tumor suppressor p53. It is identified in basal cells in the epithelial layers of a variety of tissues, including epidermis, cervix, urothelium, breast and prostate. p63 was detected in nuclei of the basal epithelium in normal prostate glands; however, it was not expressed

in malignant tumors of the prostate. As a result, p63 has been reported as a useful marker for differentiating benign from malignant lesions in the prostate, particularly when used in combination with markers of high molecular weight cytokeratins and the prostate-specific marker AMACR (P504S). p63 has also been shown to be a sensitive marker for lung squamous cell carcinomas (SqCC), with a sensitivity of ~90%. Specificity for lung SqCC, vs. lung adenocarcinoma (LADC), is approximately 80%. In breast tissue, p63 has been identified in myoepithelial cells of normal ducts.